Barclays Downgrades Polypeptide After Strong H1 Rally, Samsung Offer

3-line summary

• Barclays downgraded Polypeptide following a strong first-half rally in its shares and a Samsung acquisition offer, according to an Investing.com report.

This summary is our own processing of the source article; see the source link below for full context.